Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
71.78
-0.45 (-0.62%)
At close: Apr 28, 2026, 4:00 PM EDT
72.00
+0.22 (0.31%)
After-hours: Apr 28, 2026, 5:56 PM EDT
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 1,402 employees as of December 31, 2025. The number of employees increased by 333 or 31.15% compared to the previous year.
Employees
1,402
Change (1Y)
333
Growth (1Y)
31.15%
Revenue / Employee
$673,118
Profits / Employee
-$272,031
Market Cap
11.86B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 2,973 |
| Jazz Pharmaceuticals | 2,890 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Axsome Therapeutics | 925 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 839 |
IONS News
- 16 hours ago - Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B - Business Wire
- 7 days ago - Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting - Business Wire
- 13 days ago - Ionis to hold first quarter 2026 financial results webcast - Business Wire
- 4 weeks ago - FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy - GlobeNewsWire
- 4 weeks ago - Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market - Benzinga
- 5 weeks ago - Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review - Business Wire
- 6 weeks ago - Ionis Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - Ionis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026 - Transcripts